Arvinas (NASDAQ:ARVN – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95, FiscalAI reports. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The company had revenue of $249.70 million for the quarter, compared to analysts’ expectations of $60.71 million. During the same quarter last year, the business earned ($0.84) earnings per share. Arvinas’s revenue was up 1014.7% on a year-over-year basis.
Here are the key takeaways from Arvinas’ conference call:
- VEPPANU was approved by the FDA as the first PROTAC degrader and licensed to Rigel, which is expected to make the drug available soon. The deal and approval generated substantial Q2 revenue, including a $50 million Pfizer milestone and $62.5 million in license revenue.
- Arvinas expects multiple clinical catalysts, including initial ARV-393 BCL-6 degrader data by year-end 2026, ARV-027 muscle-exposure and degradation data in the first half of 2027, and additional ARV-102 biomarker data in October.
- ARV-393 enrollment accelerated near predicted efficacious dose levels, but most 2026 data will come from earlier, likely subtherapeutic cohorts and include an unusually high proportion of T-cell lymphoma patients. More mature monotherapy and glofitamab-combination data, including DLBCL patients, are planned for 2027.
- Regulatory requests have pushed the start of ARV-102 trials in PSP from 2026 into 2027, delaying the program’s planned phase I-B and registrational-oriented studies.
- The company reported $567.9 million in cash, cash equivalents, and marketable securities and reiterated that its cash runway extends into the second half of 2028, supporting continued investment in its early-stage oncology and neurology pipeline.
Arvinas Trading Up 11.7%
ARVN stock opened at $9.00 on Wednesday. The stock has a market capitalization of $580.68 million, a P/E ratio of -2.71 and a beta of 1.71. Arvinas has a 12 month low of $6.05 and a 12 month high of $14.51. The firm has a 50-day moving average price of $8.07 and a 200-day moving average price of $10.30.
Key Arvinas News
- Positive Sentiment: Q2 results significantly exceeded expectations: Arvinas reported earnings of $2.58 per share, compared with analyst expectations for a loss of approximately $0.24–$0.37 per share. Revenue reached $249.7 million versus the $60.7 million consensus estimate, representing 1,014.7% year-over-year growth. Arvinas Q2 earnings report
- Positive Sentiment: Regulatory and pipeline progress strengthened the investment story: The company highlighted the first regulatory approval of a PROTAC, VEPPANU, and its completed out-licensing to Rigel Pharmaceuticals. Arvinas also expects clinical data from three Phase 1 programs—ARV-393, ARV-102 and ARV-027—within the next 12 months, while reporting encouraging preclinical results for its ARV-6723 HPK1 degrader. Arvinas second-quarter 2026 results and corporate update
- Positive Sentiment: BTIG Research reaffirmed its Buy rating and maintained an $18 price target, implying substantial upside from the stock’s current level. BTIG analyst commentary
- Neutral Sentiment: Wells Fargo reaffirmed its Equal Weight rating, suggesting that despite the strong quarter and pipeline developments, the firm remains cautious about Arvinas’s longer-term outlook. Finviz analyst rating information
- Negative Sentiment: Arvinas remains unprofitable on an underlying basis, with a negative net margin and analysts forecasting a full-year loss, so the earnings beat may not represent recurring operating performance.
Analyst Ratings Changes
Several equities analysts have commented on the stock. Stephens reissued an “overweight” rating and issued a $18.00 target price on shares of Arvinas in a report on Wednesday, June 3rd. Wall Street Zen raised shares of Arvinas from a “strong sell” rating to a “sell” rating in a report on Sunday, July 26th. Barclays increased their price target on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. BTIG Research reissued a “buy” rating and issued a $18.00 price objective on shares of Arvinas in a research note on Tuesday. Finally, Weiss Ratings downgraded shares of Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Arvinas currently has a consensus rating of “Hold” and an average target price of $15.08.
Get Our Latest Stock Report on Arvinas
Insider Activity at Arvinas
In related news, insider Noah Berkowitz sold 11,108 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,413.52. Following the completion of the transaction, the insider owned 191,395 shares of the company’s stock, valued at $1,902,466.30. This represents a 5.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Randy Teel sold 9,657 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $95,990.58. Following the completion of the sale, the chief executive officer owned 287,218 shares in the company, valued at $2,854,946.92. This represents a 3.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 41,728 shares of company stock valued at $402,649. 7.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares during the last quarter. Jain Global LLC acquired a new stake in shares of Arvinas during the third quarter valued at about $95,000. Oxford Asset Management LLP boosted its stake in shares of Arvinas by 15.5% during the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after purchasing an additional 2,242 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Arvinas during the third quarter worth about $124,000. 95.19% of the stock is currently owned by institutional investors.
Arvinas Company Profile
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.
The company’s most advanced clinical candidates address hormone-driven cancers.
Featured Stories
- Five stocks we like better than Arvinas
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
